See today's BioWorld Science
To read the full story, subscribe or sign in.
Cancer

Prelude receives clearance for phase I study of SMARCA2 protein degrader PRT-3789 for solid tumors

Oct. 19, 2022
Prelude Therapeutics Inc. has received...
BioWorld Science Cancer FDA IND